Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.
Industry, Sector and Symbol
Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorComputer and Technology
CIKN/A
Phone888-280-2221
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.78 billion
Profitability
Miscellaneous
Employees5,000
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable
Covetrus (NASDAQ:CVET) Frequently Asked Questions
What is Covetrus' stock symbol?
Covetrus trades on the NASDAQ under the ticker symbol "CVET."
How were Covetrus' earnings last quarter?
Covetrus Inc (NASDAQ:CVET) issued its quarterly earnings data on Tuesday, November, 12th. The company reported $0.17 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.08 by $0.09. The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $963.69 million. Covetrus had a negative net margin of 23.15% and a positive return on equity of 4.26%. The firm's quarterly revenue was up 10.3% compared to the same quarter last year. View Covetrus' Earnings History.
When is Covetrus' next earnings date?
What price target have analysts set for CVET?
8 brokerages have issued 1-year price targets for Covetrus' shares. Their forecasts range from $11.00 to $21.00. On average, they expect Covetrus' share price to reach $15.25 in the next year. This suggests a possible upside of 17.0% from the stock's current price. View Analyst Price Targets for Covetrus.
What is the consensus analysts' recommendation for Covetrus?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Covetrus.
Has Covetrus been receiving favorable news coverage?
Media headlines about CVET stock have been trending very positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Covetrus earned a news impact score of 4.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Covetrus.
Are investors shorting Covetrus?
Covetrus saw a decrease in short interest in November. As of November 29th, there was short interest totalling 13,190,000 shares, a decrease of 7.7% from the November 14th total of 14,290,000 shares. Based on an average daily volume of 2,342,600 shares, the short-interest ratio is currently 5.6 days. Approximately 13.6% of the company's shares are short sold. View Covetrus' Current Options Chain.
Who are some of Covetrus' key competitors?
What other stocks do shareholders of Covetrus own?
Who are Covetrus' key executives?
Covetrus' management team includes the folowing people:
- Benjamin J. Shaw, President, Chief Executive Officer & Director
- Christine Tomlinson Komola, Chief Financial Officer & Executive Vice President
- Matthew Leonard, Executive VP & President-North America
- Jim Young, Chief Human Resources Officer & Senior VP
- Erin Powers Brennan, Secretary, Senior Vice President & General Counsel
Who are Covetrus' major shareholders?
Covetrus' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (2.49%), First Trust Advisors LP (1.41%), Great West Life Assurance Co. Can (0.87%), Alecta Pensionsforsakring Omsesidigt (0.56%), Gabelli Funds LLC (0.38%) and Lumbard & Kellner LLC (0.27%). Company insiders that own Covetrus stock include Benjamin Shaw, Betsy S Atkins, David Christopher Dollar, Erin Powers Brennan and Timothy Ludlow. View Institutional Ownership Trends for Covetrus.
Which major investors are buying Covetrus stock?
CVET stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, First Trust Advisors LP, Great West Life Assurance Co. Can, Alecta Pensionsforsakring Omsesidigt, Gabelli Funds LLC, Lumbard & Kellner LLC, TimesSquare Capital Management LLC and Rhumbline Advisers. Company insiders that have bought Covetrus stock in the last two years include Benjamin Shaw and Erin Powers Brennan. View Insider Buying and Selling for Covetrus.
How do I buy shares of Covetrus?
Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Covetrus' stock price today?
One share of CVET stock can currently be purchased for approximately $13.03.
How big of a company is Covetrus?
What is Covetrus' official website?
How can I contact Covetrus?
Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at 888-280-2221 or via email at [email protected]
MarketBeat Community Rating for Covetrus (NASDAQ CVET)
MarketBeat's community ratings are surveys of what our community members think about Covetrus and other stocks. Vote "Outperform" if you believe CVET will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVET will underperform the S&P 500 over the long term. You may vote once every thirty days.
